PRM61 External Validation of a Cardio-Vascular Disease Model  by Kuehne, F. et al.
for income was higher than that of health. In all cases, as often observed, hyper-
bolic discounting characterised by decreasing rate over increasing delay, was ob-
served.
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OBJECTIVES: In 2011-12, the cost-effectiveness of imatinib, dasatinib and nilotinib
for 1st-line chronic myeloid leukaemia in the UK was evaluated by NICE. We discuss
three methodological issues which strongly influence the estimated cost-effective-
ness of these drugs. These issues are also important for the cost-effectiveness of
many other drugs and medical devices.METHODS:We discuss the pros and cons of
the following competing methods. 1) Estimation of overall survival: Method A:
estimated as the cumulative duration of 1st-, 2nd- and 3rd-lines of treatments.
Method B: estimated from the surrogate responses: complete cytogenetic response
and major molecular response; 2) Cost-effectiveness of subsequent treatments: the
cost-effectiveness of 1st-line drugs are substantially affected by the cost-effective-
ness of subsequent drugs. Method A: traditional method of modelling estimated
costs and QALYs of subsequent drugs. Alternatively, minimise impact of cost-
effectiveness of subsequent treatments by either Method B: setting per patient
costs and QALYs of subsequent treatments equal between treatment arms, or
Method C: cap the cost-effectiveness ratio whilst on subsequent treatments at the
willingness to pay threshold; 3) Future drug prices: This is an important issue given
that the patent for imatinib will expire soon, in 2016, after which its price may fall
substantially. Method A: use the current list prices of all drugs in the future, as
required by NICE. Method B: assume constant drug prices until patent expiry, at
which time assume a fixed price cut. Assuming a modest 25% price cut on patent
expiry, the ICER for nilotinib vs. imatinib increases substantially, from £36,000 to
£54,000 per QALY. RESULTS: The pros and cons of the various methods are
discussed. CONCLUSIONS: This study informs important methodological issues
which apply to many health technologies. The study ultimately contributes to
more accurate assessments of the cost-effectiveness of health technologies, and
hence whether a given technology should be publicly-funded.
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OBJECTIVES: Cardiovascular disease is the leading cause of death in Germany. For
a better communication of the individual risk profile, a group of researchers of the
University of Marburg developed ARRIBA, a tool for a better communication be-
tween the general practitioners and the patient, that reports the individual 10-year
probability of a cardiovascular event. To further enhance communication and to
include lifetime risk and time-to-event estimates in this tool, we developed and
validated a state-transition microsimultion model (STMM). The focus of this pre-
sentation is on the validation of our model. METHODS: Our STMM was validated
against the results from a US observational multi-cohort study (Berry et al., 2012)
This study included data from 18 cohort studies with a total of 257,384 subjects and
estimated the lifetime risk of cardiovascular events. Our STMM was populated with
28 cohorts closely matching 7 risk profiles and 4 age groups of the observational
study and was evaluated for the time period of data collection in the observational
study. Projected outcomes were proportion experiencing myocardial infarction,
stroke, cardiovascular death, or any cardiovascular event. These outcomes were
compared to the observed outcomes. RESULTS: When comparing the lifetime risk
of experiencing any cardiovascular event estimated by the model to the observed
data, 15 and 14 of the 28 cohorts were within the 95% confidence intervals of the
observed results for men and women, respectively. The other estimates were
within two and a half times this range. Although the observational study was a
useful source for validation, the validation process was challenging with respect to
matching cohorts and outcomes. One issue is whether a validation to a US cohort
study is suitable for a European model. CONCLUSIONS: External validation in-
creased our confidence in the microsimulation model. When comparable European
data become available the validation will be repeated.
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OBJECTIVES: The memory-less feature of Markov models can be a limiting factor
when treatment-sequencing needs to be modeled and the transition probability in
second- and subsequent-line treatments are not constant. Although tunnel-states
are commonly used to model time-dependency, they can become unruly. Hence,
patient simulation models and/ or sophisticated software packages such as R are
required to model complex time dependency. An alternate method of using nested
markov models was presented at a previous conference to model time-dependency
in treatment sequence for a hypothetical model in Excel. This method is now
applied to a published model in epilepsy and results are validated using real data.
METHODS: The Wilby 2004 epilepsy model is used as a reference to derive model
inputs and validate results. It is a probabilistic treatment sequencing decision
model in epilepsy implemented using R. The nested markov method involves first
disaggregating the model by treatment, then combining the net present values of
each treatment into the treatment sequence by weighting proportional to the time
spent in the sequence, lastly followed by further discounting to account for place-
ment in the sequence. Results obtained using the nested markov methods are
validated with those published in Wilby 2004.RESULTS:Quality-adjusted life-years
obtained with the nested Markov modeling approach were similar and were within
the confidence intervals of results obtained by Wilby 2004. CONCLUSIONS: Nested
markov models can be a simple alternative to model time-dependency if transpar-
ency and less intense computational programming are required. It represents a
straightforward and intuitive approach to modeling a fixed treatment sequence,
however, it may not be suitable if the position in a sequence is inter-changeable,
and treatment effectiveness depends on the position in a sequence (e.g. cancer
therapies where disease progression impacts treatment effectiveness).
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OBJECTIVES: To assess the long-term burden of asthma in children with allergic
rhinitis/conjunctivitis. METHODS: We reviewed the literature on incidence of
asthma in patients with allergy. Furthermore we estimated long-term outcomes
associated with allergic rhinitis/conjunctivitis in children using a Markov health
state model. The model was populated using data from a long-term prospective
follow-up, where asthma status was recorded up to 10 years in patients receiving
only symptomatic treatment for allergy and asthma symptoms. The model was
used to explore the impact of key drivers of long-term patient outcomes. Burden to
patient was measured as the difference between net present value of QALYs and
life-years. RESULTS: Allergic rhinitis/conjunctivitis in childhood is associated with
a risk of developing asthma. The asthma risk is highest at younger age and de-
creases as the child reaches adolescence and adult age. Furthermore, allergic rhi-
nitis is a risk factor for childhood allergic asthma to persist into middle age. The
model analysis showed that in per one hundred 10-year old patients with hay fever,
but no previous asthma: 57 will develop asthma over a 10 years horizon; In total 55
QALYs are lost over a 10 years horizon of which 67% is attributable to allergic
asthma; and Additional 23 respectively 43 QALYs are lost when analyzing on a 15
respectively 20 years horizon even when assuming no additional cases occur after
year 10.CONCLUSIONS:Childhood allergic rhinitis is a risk factor for developing allergic
asthma in childhood/ preadolescence. Allergic asthma in turn has a pro-found effect on
the long-term burden of allergic rhinitis/conjunctivitis. Literature suggests that childhood
asthma may impact on quality of life also when the patient reaches middle age. Taken
together this suggests a large potential for specific immunotherapy with disease-modify-
ing properties to reduce the burden of allergy and allergic asthma.
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OBJECTIVES: Bayesian mixed treatment comparison models (MTCs) provide a
powerful methodology to obtain estimates of relative efficacy between alternative
treatments when head to head evidence is not available or not sufficient. Most
evaluations only consider evidence from randomized controlled trials (RCTs),
while information from other trial designs is ignored. In this work we propose 3
methods to extend MTC models to systematically include evidence from different
trial designs using an application in Rheumatoid Arthritis (RA). METHODS: A sys-
tematic literature review identified 13 RCTs and 3 observational trials assessing the
treatment effects of five anti-TNF agents currently licensed in Europe. Naïve Pool-
ing does not differentiate between designs, one simply pools across all studies. It is
not possible to down-weight designs of lesser quality or to adjust for bias. Alterna-
tively observational data can be analysed separately and the results used to inform
the prior distribution for the RCT model. This allows for bias adjustments and
controlling the influence on the overall effect. In addition to that, a 3-level hierar-
chical model allows the direct comparison of estimates on study type level to
overall level. The method accounts for between trial design heterogeneity; overall
estimates become more conservative when study type estimates differ. RESULTS:
Including evidence from observational trials to estimate the relative efficacy be-
tween anti-TNF agents in RA has strengthened our belief in the effect estimates.
Overall, the observational trial data found less difference between the agents than
was suggested by RCT evidence only. CONCLUSIONS: Observational data is avail-
able for many disease areas providing additional information on treatment effec-
tiveness. We think it is important for an informed decision making process to
include all available evidence. The proposed techniques provide a framework for
systematically including evidence from different trial designs in a MTC model.
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